Isatuximab is under clinical development by Sanofi and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Isatuximab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Isatuximab (Sarclisa) is a monoclonal antibody acts as anticancer agent. It is formulated as solution and concentrate for solution for intravenous route of administration. Sarclisa is indicated for treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, and relapsed or refractory multiple myeloma.
Isatuximab (SAR650984) is under development for the treatment of relapsed or refractory natural killer cell lymphoma, T-cell lymphomas, amyloidosis, autoimmune hemolytic anemia, pediatric patients for the treatment of relapsed/refractory acute lymphoblastic leukemia and relapsed/refractory acute myeloid leukemia, as a second line therapy for hepatocellular carcinoma (HCC), recurrent glioblastoma multiforme (GBM) and epithelial ovarian cancer (EOC), hematological malignancies including B-cell non-Hodgkin-lymphoma/leukemia (NHL), acute myeloid leukemia (AML), metastatic colorectal cancer, chronic lymphocytic leukemia (CLL), plasma cell myeloma, smoldering multiple myeloma and relapsed and refractory multiple myeloma. It is administered through intravenous and subcutaneous routes. The drug candidate is a naked humanized monoclonal antibody targeting CD38 antigen. It is a new molecular entity (NME). It was also under development for the treatment of non-small cell lung cancer, metastatic castration-resistant prostate cancer, as a third line therapy for recurrent metastatic squamous cell carcinoma of the head and neck (SCCHN), T-cell acute lymphoblastic leukemia (T-ALL), diffuse large b-cell lymphoma, peripheral T-cell lymphoma, mantle cell lymphoma and acute lymphoblastic lymphoma.
It was also under development for the treatment of classic Hodgkin's lymphoma.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of Isatuximab’s drug-specific PTSR and LoA scores, buy the report here.